| Literature DB >> 15717328 |
Chun-Ming Huang1, Zhongkai Shi, Tivanka S DeSilva, Masato Yamamoto, Kent R Van Kampen, Craig A Elmets, De-chu C Tang.
Abstract
We created an anti-tumor vaccine by using adenovirus as a vector which contains a cytomegalovirus early promoter-directed human carcinoembryonic antigen gene (AdCMV-hCEA). In an attempt to develop the skin patch vaccine, we epicutaneously vaccinated Balb/c mice with AdCMV-hCEA. After nine weeks post-immunization, vaccinated mice evoked a robust antibody titer to CEA and demonstrated the capability of suppressing in vivo growth of implanted murine mammay adenocarioma cell line (JC-hCEA) tumor cells derived from a female Balb/c mouse. Proteomic analysis of the tumor masses in the non-vaccinated naive and vaccinated mice reveal that six proteins change their abundance in the tumor mass. The levels of adenylate kinase 1, beta-enolase, creatine kinase M chain, hemoglobin beta chain and prohibitin were statistically increased whereas the level of a creatine kinase fragment, which is undocumented, was decreased in the tumor of vaccinated mice. These proteins may provide a vital link between early-stage tumor suppression and immune response of skin patch vaccination.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15717328 PMCID: PMC3035721 DOI: 10.1002/pmic.200401114
Source DB: PubMed Journal: Proteomics ISSN: 1615-9853 Impact factor: 3.984